Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 37: 2062-2068, 1991;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shaw, L. M.
Right arrow Articles by Mattes, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shaw, L. M.
Right arrow Articles by Mattes, R.

Clinical Chemistry, Vol 37, 2062-2068, Copyright © 1991 by American Association for Clinical Chemistry

Ultrasensitive measurement of delta-9-tetrahydrocannabinol with a high energy dynode detector and electron-capture negative chemical- ionization mass spectrometry

LM Shaw, J Edling-Owens and R Mattes
Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia 19104.

Plasma concentrations of delta-9-tetrahydrocannabinol, the principal psychoactive cannabinoid in marijuana, decline to values substantially less than 1 microgram/L within a few hours after a subject has smoked a marijuana cigarette. Using a single-quadrupole gas chromatograph-mass spectrometer (GC/MS) operated in the negative chemical-ionization mode and retrofitted with a High Energy Dynode detector system, we measured delta-9-tetrahydrocannabinol and a primary metabolite, 11-nor-delta-9- tetrahydrocannabinol-9-COOH. Using a trifluoroacetic anhydride derivatization procedure and the High Energy Dynode detector system, we improved by 6.25-fold the limit of detection for delta-9- tetrahydrocannabinol in plasma over that obtained with the same GC/MS system without the new detector (80 vs 500 ng/L). The new detector system will thus permit further investigation of the post-distribution pharmacokinetics of delta-9-tetrahydrocannabinol and detection of delta- 9-tetrahydrocannabinol in plasma for a longer time after ingestion of the drug in forensic cases. The High Energy Dynode detector system should be applicable to a wide variety of other GC/MS analyses that require significantly improved sensitivity.


The following articles in journals at HighWire Press have cited this article:


Home page
 NEJMHome page
J. A. Grisso, D. F. Schwarz, N. Hirschinger, M. Sammel, C. Brensinger, J. Santanna, R. A. Lowe, E. Anderson, L. M. Shaw, C. A. Bethel, et al.
Violent Injuries among Women in an Urban Area
N. Engl. J. Med., December 16, 1999; 341(25): 1899 - 1905.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Association for Clinical Chemistry.